Publications: group B Streptococcus

2000 to Present:

• Hawkins PA, Law CS, Metcalf BJ, et al. Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA. J Antimicrobial Therapy. In press.
• Metcalf BJ, Chochua S, Gertz RE Jr, et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the United States. Clin Microbiol Infect. 2017 Feb 28. pii: S1198–743X(17)30118–0.
• Schrag SJ, Farley MM, Petit S, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005–2014. 2016;138(6):e20162013–e20162013.
• Smith EM, Khan MA, Reingold A, Watt JP. Group B Streptococcus infections of soft tissue and bone in California adults, 1995–2012. Epidemiol Infect. 2015;143(15):3343–50.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2014.
• Kim SY, Russell L, Park J, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014;32(17):1954-63.
• Park C, Nichols M, Schrag, SJ. Two cases of invasive vancomycin-resistant group B Streptococcus New Engl J Med. 2014;370(9):885-86.
• Verani J, Spina NL, Lynfield R, et al. Early-onset group B streptococcal disease in the United States: Potential for further reduction. Obstet Gynecol. 2014;123(4):828-37.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2013[1 page].
• Fairlie T, Zell ER, Schrag SJ. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. Obstet Gynecol. 2013;121(3):570-7.
• Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine. 2013;31(Suppl 4):D52-7.
• Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31(Suppl 4):D20-6.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2012[1 page].
• Koumans EH, Rosen J, Van Dyke MK, et al. Prevention of mother-to-child transmission of infections during pregnancy: Implementation of recommended interventions, United States, 2003-2004. Am J of Obstet Gynecology. 2012;206(2):158.e1-158.e11.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2011.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2010.
• Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease — revised guidelines from CDC, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:RR-10.
• Centers for Disease Control and Prevention. Trends in perinatal group B streptococcal disease – United States, 2000-2006. MMWR Morb Mortal Wkly Rep. 2009;58(5):109-12.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2009.
• Kothari NJ, Morin CA, Glennen A, et al. Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003-2007. Emerg Infect Dis. 2009;15(8):1279-81.
• Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis. 2009;49(1):85-92.
• Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B Streptococcus. New Engl J Med. 2009;360(25):2626-36.
• Castor M, Whitney CG, Como-Sabetti K, et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Ob Gyn. 2008;2008:727505.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2008.
• Dahesh S, Hensler ME, Van Sorge NM, et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52(8):2915-8.
• Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: A multi-state, population-based analysis. Ped Infect Dis J. 2008;27:1057-64.
• Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056-65.
• Phares CR, Schuchat A, Schrag SJ. Invasive group B streptococcal disease in the United States. JAMA. 2008;300(14):1650.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2007.
• Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B sreptococcal disease in the United States, 1999-2005. JAMA. 2007;299(17):2056-65.
• Centers for Disease Control and Prevention. Perinatal group B streptococcal disease after universal screening recommendations — United States, 2003-2005. MMWR Morb Mortal Wkly Rep. 2007;56(28):701-5.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2006.
• Schrag SJ, Hadler J, Arnold KE, et al. Risk factors for invasive perinatal Escherichia coli sepsis in the era of widespread intrapartum antibiotic use. Pediatrics. 2006;118(2):570-6.
• Schrag SJ, Stoll BJ. Early-onset neonatal sepsis in the era of wide-spread intrapartum chemoprophylaxis. Ped Infect Dis J. 2006;25(10):939-40.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2005.
• Centers for Disease Control and Prevention. Early-onset and late-onset neonatal group B streptococcal disease – United States, 1996-2004. MMWR Morb Mortal Wkly Rep. 2005;54(47):1205-8.
• Eisenberg E, Craig AS, Gautam S, et al. Prevention strategies for perinatal group B streptococcal disease: Beyond screening. Ped Infect Dis J. 2005;24:520-4.
• Law MR, Palomaki G, Alfirevic Z, et al. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J Med Screen. 2005;12:60-8.
• Morin CA, White K, Schuchat A, Danila RN, Lynfield R. Perinatal group B streptococcal disease prevention, Minnesota. Emerg Infect Dis. 2005;11(9):1467-9.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2004.
• Centers for Disease Control and Prevention. Diminishing racial disparities in early-onset neonatal group B streptococcal disease, United States, 2000-2003. MMWR Morb Mortal Wkly Rep. 2004;53(No.RR-23):502-5.
• Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal disease. MMWR Morb Mortal Wkly Rep. 2004;53(No.RR-23):506-9.
• Balter S, Zell ER, O’Brien K, et al. Impact of intrapartum antibiotics on the care and evaluation of the newborn. Pediatr Infect Dis. 2003;22:853-7.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2003.
• Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis. 2003;3(4):201-13.
• Schrag SJ, Arnold KE, Mohle-Boetani JC, . Prenatal screening for infectious diseases and opportunities for prevention. Obstet Gynecol. 2003;102:753-60.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2002.
• Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. MMWR. 2002;51(No.RR-11):1-22.
• Hyde TB, Hilger TM, Reingold A, Farley MM, O’Brien KL, and Schuchat A for the Active Bacterial Core surveillance (ABCs) of the Emerging Infections Program Network. Trends in the incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics. 2002;110(4):690-5.
• Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. New Engl J Med. 2002;347:233-9.
• Schuchat A, Roome A, Zell ER, Linardos H, Zywicki S, O’Brien KL. Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections. Maternal Child Health J. 2002;6(2):107-14.
• Baltimore RS, Huie SM, Meek JI, Schuchat A, O’Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics. 2001;108(5):1094-8.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2001.
• Farley MM. Group B streptococcal infections in nonpregnant adults. Clin Infect Dis. 2001;33:556-61.
• Henning KJ, Hall EL, Dwyer DM, et al. Invasive group B streptococcal disease in Maryland nursing home residents. J Infect Dis. 2001;183:1138-42.
• Schuchat A. Group B streptococcal infections: from trials and tribulations to triumph and trepidation. Clin Infect Dis. 2001;33:751-6.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2000.
• Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers- Connecticut and Minnesota. MMWR Morb Mortal Wkly Rep. 2000;49(11):228-32.
• Centers for Disease Control and Prevention. Early-onset group B streptococcal disease, United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 2000;49(35):793-6.
• Centers for Disease Control and Prevention. Hospital-based policies for prevention of perinatal group B streptococcal disease, United States 1999. MMWR Morb Mortal Wkly Rep. 2000;49(41):936-40.
• Factor SH, Whitney CG, Zywicki SS, Schuchat A for the Active Bacterial Core Surveillance Team. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. Obstet Gynecol. 2000;95:377-82.
• Hager WD, Schuchat A, Gibbs R, Sweet R, Mead P, Larsen JW. Prevention of perinatal group B streptococcal infection: addressing current controversies. Obstet Gynecol. 2000;96:141-5.
• Schrag S, Whitney CG, Schuchat A. Neonatal group B streptococcal disease: How infection control teams can contribute to prevention efforts. Infect Control Hosp Epidemiol. 2000:473-83.
• Schrag SJ, Zywicki S, Farley M, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342:15-20.
• Schuchat A, Schrag S. Group B Streptococcus: from emerging infection to prevention success story. In: Scheld WM, Craig WA, Hughes JM. Emerging Infections 4. Washington, DC: American Society for Microbiology. 2000:107-20.

 Top of Page

 1995-1999:

• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1999.
• Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting. MMWR Morb Mortal Wkly Rep. 1999;48(20):426-8.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1998.
• Centers for Disease Control and Prevention. Adoption of hospital policies for prevention of perinatal group B streptococcal disease – United States, 1997. MMWR Morb Mortal Wkly Rep. 1998;47(32):665-70.
• Harrison LH, Elliot JA, Libonati JP, et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis. 1998;177:998-1002.
• Wessels MR, Kasper DL, Johnson KD, Harrison LH. Antibody responses in invasive group B streptococcal infection in adults. J Infect Dis. 1998;178:569-72.
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 1997.
• Centers for Disease Control and Prevention. Decreasing incidence of perinatal group B streptococcal disease — United States, 1993-1995. MMWR Morb Mortal Wkly Rep. 1997;46(21):473-7.
• Rosenstein NE , Schuchat A, and the Neonatal Group B Streptococcal Disease Study Group. Opportunities for prevention of perinatal group B streptococcal disease: a multi-state surveillance analysis. Obstet Gynecol. 1997;90:901-6.
• Whitney C, Plikaytis BD, Gozansky W, Schuchat A, Neonatal group B streptococcal disease study group. Prevention practices for perinatal group B streptococcal disease: a multistate surveillance analysis. Obstet Gynecol. 1997;89:28-32.
• Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis. 1996;173:365-73.
• Jackson L, Farley M, Schuchat A. Adult group B streptococcal disease. Ann Int Med. 1996;125;152-3.
• Schuchat A, Whitney C, Zangwill K. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep. 1996;45 (RR-7):1-24.
• Farley MM. Group B streptococcal infection in older patients: Spectrum of disease and management strategies. Drugs and Aging. 1995;6:293-300.
• Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med. 1995;123:421-7.
• Jackson L, Hilsdon R, Farley M, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med. 1995;123:415-20.

 Top of Page

1992-1994:

• Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. Pediatr Infect Dis J. 1994;13:623-9.
• Farley MM, Harvey RC, Stull T, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med. 1993;328:1807-11.
• Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection: A population-based economic analysis. JAMA. 1993;270:1442-8.
• Zangwill KM, Schuchat A, Wenger JD, and the Group B Streptococcal Disease Study Group. Group B streptococcal disease in the United States: Report from a multistate active surveillance system. MMWR Morb Mortal Wkly Rep. 1992;41[No. SS-6]:25-32.

 Top of Page